{"name":"Gan and Lee Pharmaceuticals, USA","slug":"gan-and-lee-pharmaceuticals-usa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GZR-18","genericName":"GZR-18","slug":"gzr-18","indication":"Other","status":"phase_1"},{"name":"Gan & Lee insulin glargine followed by Lantus","genericName":"Gan & Lee insulin glargine followed by Lantus","slug":"gan-lee-insulin-glargine-followed-by-lantus","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"GZR4 Injection","genericName":"GZR4 Injection","slug":"gzr4-injection","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"Gan & Lee Insulin Glargine Injection","genericName":"Gan & Lee Insulin Glargine Injection","slug":"gan-lee-insulin-glargine-injection","indication":"Type 1 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"GZR-18","genericName":"GZR-18","slug":"gzr-18","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GZR4 Injection","genericName":"GZR4 Injection","slug":"gzr4-injection","phase":"phase_3","mechanism":"GZR4 Injection is a glucagon receptor antagonist.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Gan & Lee Insulin Glargine Injection","genericName":"Gan & Lee Insulin Glargine Injection","slug":"gan-lee-insulin-glargine-injection","phase":"phase_3","mechanism":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Gan & Lee insulin glargine followed by Lantus","genericName":"Gan & Lee insulin glargine followed by Lantus","slug":"gan-lee-insulin-glargine-followed-by-lantus","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN1ZrS1NxNXV6cG16bHpTR09LdHNuZW02aVhyWmpNRFV4N3FISmxwM0hWbzFGeTVpeXhZZWc5NU9kVVh1TkVMYnlkRTA3QjdqNXRlMUdzSFBqc0Y1b1pxXy1vV2R2LTRnNmJVY21nd3hQRFZlZHpLWVhHcTJkYTh0Q05PdjlQN3J4Z2g2S0xiODNUUlRzVGh6cUFZZlhtU19QcFV5ZnhOcmlRWUFsZzZMdjFVd2hFazJDOHlpZWZwUmNRZw?oc=5","date":"2026-04-01","type":"trial","source":"BioPharma APAC","summary":"Gan And Lee Pharmaceuticals Reports Phase 3 Success For Once Weekly Insulin GZR4 - BioPharma APAC","headline":"Gan And Lee Pharmaceuticals Reports Phase 3 Success For Once Weekly Insulin GZR4","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQVmxYQjJQTk9ILXZtVXRwbkl2N01MSUIwM0lPa3lfS0M0N29NeklWNUpKR2NndGVqZzBOUTZVcWxaU184ZHdXZVVaRXFCSTN2dExsRC1lcXE4SFlieVRCc1VnaTdMQ094dlpjMWtkUlNxczFKbVl5VW91T192R2U2ZTZTUTVvY3FiaDdJNVBmeWJDUDhLNGVuM0pZbkJBbHBxb1BRUDVSWVFIWjZic3libmdycmVYTk1WRjQ3dmw0LUF5WTBRRm5DX2dJU0ZZUTFINTR1YWFnV3c2aGNVYnBvaUFKN19idw?oc=5","date":"2026-01-20","type":"pipeline","source":"هيئة الدواء المصرية","summary":"EDA Chairman Discusses Localization of the Pharmaceutical Industry with Gyptho Pharma and China’s Gan & Lee - هيئة الدواء المصرية","headline":"EDA Chairman Discusses Localization of the Pharmaceutical Industry with Gyptho Pharma and China’s Gan & Lee - هيئة الدوا","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNcTB4YW1Rek9DQmUwWFZDc3B2b2FsOGs4SnE5YWhFdWpIUENXTUtoVG5WbGhtZURINk1iYVUySXptRVFzZFJicEM4eG82eHZvZW1OQmJ2eW5ZZUU0ZEYySnhpbERHTExoZzlTc0phVm1tdzBLYkdxRFhQdnhkektjZ1AtUW5kRGFjMXZ1SFQzZzFURWNzZkN2MVVMdUd2U294T0xkdjZR?oc=5","date":"2025-12-31","type":"deal","source":"The Pharma Letter","summary":"Lupin signs exclusive GLP-1 licensing deal with Gan & Lee - The Pharma Letter","headline":"Lupin signs exclusive GLP-1 licensing deal with Gan & Lee","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQy1wZ3RaVF93b1VaOXJOSlJscnQyVjdza1k1QXRVVHVMV0JXM29sX0xFOUFmdUdvWW5sUmxGQzNGdXhUNkVoN0h3OGdxbWtHbFVXdTYzM2o3dDU2Vjc5dnd3S210R3JycFlSQ2h1dGMyRU9wWVVsdTBXT3Z2dHVzVm0wMzNyRk1kVHV2ODFLbFRQNlBFWnRGRVVPOFZuVnd5a3RKNFhFQ3pCT2ZHdmFqaThid01raVBEa2FjT3pNbmJRM1FScFFKeHVZVFJyWGJPU1AtSnhReFh2YjFWYks4VTVn0gHnAUFVX3lxTFBONG1ERTdmUEJEVVg0QTQyelBSSDc2UEtIOE01WDRSY1NIRDBDNTVXUjlUdldfaXdGUVQtdmdrY0JCY2UtRk45a3N5TGpReGxUQWVHVW9jY0lXaUlXUC1wSXVDSUZVS2d5ZG5JbXUwd3hlbXhrX0pmRjQzcmp2TGc5NW5DU0hTa1lrYjByZ05UTHVVRG5MU002MDZMYXZqdHljNXJuWXl3Skgta2F1N0pYUHBybGdPQThROUtsVm5oVHNvMGJPVjFsN3RsWTBhSVhxck43a2pyWXQ3blEyd3B3YmJCWUs3MA?oc=5","date":"2025-12-30","type":"deal","source":"ET Pharma","summary":"Lupin in-licenses fortnightly weight-loss drug from China’s Gan & Lee Pharma - ET Pharma","headline":"Lupin in-licenses fortnightly weight-loss drug from China’s Gan & Lee Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQUFBEcF9WNkRibEVHMWdqSHNZajViNWdCUXU1U3hQTk9QMG5aLTlfUVNjVzcxcVBuX2N2ZllBcGZfRzlHa2VzUmE3S0NGX196SkNQMXRzcTE5aVI0Y0xIWHFIYTVWNkNBdWRkR2dKajgzcGJrVE54UGg1YUJKV0RoTmZBSW5saFl6Znd3M01Cb1BFT1BucTdRQ3Q1Y29nYzFHcXc2aDJvRkRfdGVXOUZYc1NDMjFiZkxxNWQyV2d6NHIxLUJuQl9pR0xmNnR1SlJiOHZWd2YxQjExLTQ?oc=5","date":"2025-12-30","type":"pipeline","source":"Dalal Street Investment Journal","summary":"Global Pharma Major-Lupin Signs Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist - Dalal Street Investment Journal","headline":"Global Pharma Major-Lupin Signs Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQVHdjS0tYY3MyT29XaWRNYjMtVTJGbDkwVmVycmx6VGh4Y3Y2cEZOTTdON180RlFzeU1jckZRQl9PcnR4QTlnbzcxbG5jVG9nUWxjZkRYaFJydkxzRmZKU0FTTHhFdVhCTlNWNmgyYjhtWExKb2huczBJZUQtSjlXVklIZDJ0eHZDam80MGhtMzZfVkMzZ3JiNHVvR0NsNlJqQjdqaTJSLV93OFNnUmt6VTNEZDZRZ0tvLThfMjM4YzVVYUFhTDNGcDVUQjBUc2ZJRWZ5ZXRYWUVpV0hqWFZJ?oc=5","date":"2025-12-29","type":"pipeline","source":"lupin.com","summary":"Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist - lupin.com","headline":"Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbWNjVXJuUjg1TTY5Y016eW8tOEpWZjRsMl96NkNJUWF6MnhhTFdMOXhZelB6emJlX2lsS2ZBWE5oWmRxV3NzU0ZkN08xWExlNEZlc0Zkb2FzOGlIeG4tREZMc1ZCd0pCcTZXQVgzNWVHTjlnNEtlMDY2M0VWSGZ1WDVDcUQxaDhxSFNVVDdTWnc5UHk1NlVZc1FDbS1Sbk1PWWFlSzQxTGkwZUNRNE1nMl83b3ctd0VxaDJ4WUhjLTF4MEE?oc=5","date":"2025-12-29","type":"pipeline","source":"BioSpectrum Asia","summary":"Lupin signs agreement with Gan & Lee Pharma for novel GLP-1 receptor agonist - BioSpectrum Asia","headline":"Lupin signs agreement with Gan & Lee Pharma for novel GLP-1 receptor agonist","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-30","type":"trial","source":"Indian Pharma Post","summary":"Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab - Indian Pharma Post","headline":"Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1Ul9NcllDbFdhS3BPODRoV0FNYmJpU0l5Y2NTRklDLTRGbUNuX2IyaE5IelRmRlAxcy1ObDMtYW9NTTEyeHZhSWRhZ0cwMHo0S0h3?oc=5","date":"2025-11-27","type":"trial","source":"FirstWord Pharma","summary":"Gan & Lee starts Phase III study in China for once-monthly GLP-1 shot - FirstWord Pharma","headline":"Gan & Lee starts Phase III study in China for once-monthly GLP-1 shot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPcUwzbEJJVWVpSVNnZ1dVM2cxYkt3Y3ZCcV9GTkIySU5MeDlzcDR0UVc3NEtVX3RsNUR6eXcybUV2SWNzUHE5MUpZbms5S1MwU3EzcnJkVE9pSTBpSTlFV0VTazl1SE8zTV82MFo1SnBmTGRKM01GMjF1X0FCLUwzTTJGMXRHY2dvNVJnU1VlWlZDcTluS2h2VExDRjNpUmRHdVFtNGt3MWl0YkY4bEo5bE5DeE4tellpRmh0LVVuZGl3LUlyR0VaTDFQcE1nVUp5?oc=5","date":"2025-09-24","type":"deal","source":"Yicai Global","summary":"China's Gan & Lee Soars on Deal to Supply Insulin Injections, Pens to Brazilian Public Health Institution - Yicai Global","headline":"China's Gan & Lee Soars on Deal to Supply Insulin Injections, Pens to Brazilian Public Health Institution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQNjI5aFkwV25rcDQxdktxbHppUmh4QVZrOWdtMXZtRmZwR01nZDFuNDI0NkNLdTVyRmZ3Wm9jOGxIaHkteDhWV1dpaWM4M053SE0yWnRxbVRYWWFwWWc3djFmUFdWRFhaTU9XUzNFcjA0aDJHSzljXzEyTzZFNzNXc1F2eDRXOEpKSDRiREF5eEJUbEhVSnRYV3pjY19jeUxSR3I5MlpsckttRTF4TGxYYlBQcWlyemc3V0Q1RTJBeDExRDA1Zk9wQ3JCVGtsbzd3akZVUzVqdmwxSml2SFZYV2Z1ZlJWdXNwT0FaZklHQS1BTUtNRHVmRFBvcjZBYXk1ZHV5NG9wSVBlSE56RXgyYnZyelRGbmp0YmU3aExjY3dwbTVF?oc=5","date":"2025-06-21","type":"pipeline","source":"PR Newswire","summary":"Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions - PR Newswire","headline":"Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPX3pDV2M3dkNRVHBqM2MzcnFpamcyZDRXQXVfNFdId2JIUlFhVE9TSXdLSDYyOEpDTXJZUjV2OE5DYlNxd0RYdVFnZEtTRnFqYlR5R29uUFBlQjFVbjVFcjFQWk1VbGNxdXdpMWtFeFFjQzVHRzhjc3hwcWtFQkFPOXd3VEtFeDJ5aUJ5WlY3bVlQM2pZNExUd1lRNnZaUVhULTZ2ekV4azVQZFpKNDMxRGdXaTdJM3gxanROaHlfQU5DeWRISW91X09nNXdHT2Npa0puRHhzWFhTOGRxODJmLUQwRndXRHBhQkxJSFhtNnh0VTRUd001M3B2WTFHY2lCcDhzU0NZRy1WcFRsSU5XTTNHYnJCQ2lJYmxOOU52VFFoWURtekROV256S0VoUQ?oc=5","date":"2025-03-10","type":"trial","source":"PR Newswire","summary":"Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity - PR Newswire","headline":"Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Inj","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}